Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.
暂无分享,去创建一个
G. Mufti | S. Iacobelli | J. Sierra | R. Brand | R. Martino | M. Boogaerts | D. Niederwieser | A. Bacigalupo | T. D. de Witte | J. Jouet | J. Finke | T. Ruutu | A. van Biezen | R. Barge | A. Devergie | D. Beelen | M. Falda | J. Reiffers | T. Jansen | E. Alessandrino
[1] C. Rubio. Marqués de Valdecilla , 2007 .
[2] A. Artz. Comorbidity and beyond: pre-transplant clinical assessment , 2005, Bone Marrow Transplantation.
[3] J. Briones,et al. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] F. Appelbaum. Immunobiologic therapies for myelodysplastic syndrome. , 2004, Best practice & research. Clinical haematology.
[5] G. Mufti,et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. , 2004, Blood.
[6] M. Munsell,et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.
[7] John P Klein,et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. , 2004, Blood.
[8] S. Giralt. Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions. , 2004, Current hematology reports.
[9] R. Storb,et al. Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care , 2004, Journal of Cancer Research and Clinical Oncology.
[10] A. Zander,et al. Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. , 2004, Annals of hematology.
[11] D. Blaise,et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. , 2003, Blood.
[12] N. Schmitz,et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases , 2003, Annals of Hematology.
[13] N. Kröger,et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia , 2003, Annals of Hematology.
[14] J. Garcia-conde,et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. , 2002, Blood.
[15] G. Mufti,et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced‐intensity conditioning compared with standard preparative regimens , 2002, British journal of haematology.
[16] John P Klein,et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. , 2002, Blood.
[17] J. Sierra,et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. , 2002, Blood.
[18] R. Brand,et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. , 2002, Blood.
[19] C. Craddock,et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. , 2002, Blood.
[20] B. Sandmaier,et al. Non-myeloablative transplantation. , 2002, Hematology. American Society of Hematology. Education Program.
[21] A. Gratwohl,et al. Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation , 2001, Leukemia.
[22] N. Keiding,et al. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling , 2001, Bone Marrow Transplantation.
[23] N Keiding,et al. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis , 2001, Bone Marrow Transplantation.
[24] A. Hagemeijer,et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. , 2001, Blood.
[25] E. Estey,et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia , 2001, American journal of hematology.
[26] G. Morgan,et al. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. , 2001, Cytotherapy.
[27] G. Meloni,et al. Haematopoietic stem cell transplantation for patients with myelo‐dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) , 2000, British journal of haematology.
[28] J. Anderson. Bone marrow transplantation for myelodysplasia. , 2000, Blood reviews.
[29] J. Wingard,et al. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy) , 2000, Bone Marrow Transplantation.
[30] H. Deeg,et al. Hemopoietic stem cell transplantation for myelodysplastic syndrome , 2000, Current opinion in oncology.
[31] H. Deeg,et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. , 2000, Blood.
[32] Raiola,et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation , 2000, British journal of haematology.
[33] F. Appelbaum,et al. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. , 1998, Leukemia.
[34] M. Labopin,et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome , 1998, Bone Marrow Transplantation.
[35] M. Labopin,et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1998, Bone marrow transplantation.
[36] J. Magaud,et al. Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint , 1998, Leukemia.
[37] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[38] K. Sullivan,et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS‐related acute myeloid leukaemia , 1996, British journal of haematology.
[39] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[40] J. Bennett. Secondary acute myeloid leukemia. , 1995, Leukemia research.
[41] J. Neuwirt. Institute of hematology and blood transfusion: its role in the health care of today. Introductions. , 1993, Stem cells.
[42] F. Appelbaum,et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. , 1990, Blood.
[43] A. Gratwohl,et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) , 1990, British journal of haematology.
[44] W. Peart,et al. A university hospital. , 1970, Proceedings of the Royal Society of Medicine.
[45] THE ALFRED HOSPITAL , 1920 .
[46] Z. Cope. The National Hospital , 1900, The Hospital.